medigraphic.com

2011, Número 4

<< Anterior Siguiente >>

Rev Med MD 2011; 2.3 (4)


Yin-Yang del Factor Nuclear-κ B, su rol en inflamación, respuesta inmune y cáncer

Ortiz-Lazareno PC, Lerma-Díaz JM, Domínguez-Rodríguez JR, Hernández-Flores G, Sierra-Díaz E, Bravo-Cuéllar A

Idioma: Español
Referencias bibliográficas: 50
Paginas: 198-205
Archivo PDF: 629.58 Kb.


RESUMEN

El factor nuclear-κ B (NF-κ B) es un regulador importante de la inmunidad e inflamación, siendo un elemento clave en el desarrollo y progresión de tumores malignos. Estímulos como productos bacterianos, virales, citocinas proinflamatorias y estrés oxidativo producen su activación, la cual desencadena la expresión de genes involucrados en el control de la respuesta inmune y del proceso inflamatorio. Como consecuencia de la actividad biológica de este factor, inicia una compleja red de retroalimentación negativa organizada, que permite el restablecimiento de la homeostasis una vez que se elimina el agente extraño. El NF-κ B representa un arma de dos filos, ya que por una parte es esencial para una adecuada respuesta inmune a una variedad de condiciones de estrés ambiental pero el incremento en su actividad puede desencadenar procesos de inflamación crónica y cáncer. Los mecanismos que permiten la persistencia en la activación de NF-κ B no son claros pero involucran defectos en vías de señalización, mutaciones o rearreglos cromosomales. Este factor tiene un gran potencial como blanco terapéutico en enfermedades inflamatorias crónicas y en cáncer.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Baltimore D. Discovering NF-κB. Cold Spring Harb Perspect Biol. 2009 Jul; (1) 1-3.

  2. 2.Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002 Oct;2(10):725-734.

  3. 3.Rahman MM, McFadden G. Modulation of NF-κB signalling by microbial pathogens. Nat Rev Microbiol 2011 Abr;9(4):291-306.

  4. 4.Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis. Rheumatology. 2008 May 1;47(5):584 -590.

  5. 5.Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011 Ene 5;13(1):11-22.

  6. 6.Liu SF, Malik AB. NF-κB activation as a pathological mechanism of septic shock and inflammation. American Journal of Physiology - Lung Cell Mol Phys. 2006 Abr 1;290(4):L622 -L645.

  7. 7.Okamoto T. NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006 Dic;6(4):359-372.

  8. 8.Wang S, Liu Z, Wang L, Zhang X. NF-κ B signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009 Oct;6(5):327-334.

  9. 9.Okamoto T, Sanda T, Asamitsu K. NF-κ B signaling and carcinogenesis. Curr Pharm Des 2007;13(5):447-462.

  10. 10.Ban JO, Oh JH, Son SM, Won D, Song HS, Han SB, et al. Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NF-kB via suppression of GSK-3β expression. Cancer Biol Ther. 2011;12(4).

  11. 11.Bravo-Cuellar A, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy A, et al. Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence. Mol Cancer. 2010;9(1):114.

  12. 12.Gordon JW, Shaw JA, Kirshenbaum LA. Multiple Facets of NF-κ B in the Heart: To Be or Not to NF-{kappa}B. Circ Res 2011 Abr 29;108(9):1122-1132.

  13. 13.Chen ZJ. Ubiquitin signalling in the NF-κ B pathway. Nat Cell Biol. 2005;7(8):758-765.

  14. 14.Chen ZJ, Sun LJ. Nonproteolytic Functions of Ubiquitin in Cell Signaling. Molecular Cell. 2009 2;33(3):275-286.

  15. 15.Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 2011 Mar 31;471(7340):591-596.

  16. 16.Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. EMBO Rep. 2008 Jun;9(6):536-542.

  17. 17.Oeckinghaus A, Ghosh S. The NF-κB Family of Transcription Factors and Its Regulation. Cold Spring Harb Perspect Biol. 2009 Oct;1(4).

  18. 18.Ikeda F, Deribe YL, Skånland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature. 2011 Mar 31;471(7340):637-641.

  19. 19.Yin XJ, Ma JYC, Antonini JM, Castranova V, Ma JKH. Roles of Reactive Oxygen Species and Heme Oxygenase-1 in Modulation of Alveolar Macrophage-Mediated Pulmonary Immune Responses to Listeria monocytogenes by Diesel Exhaust Particles. Toxicol Sci. 2004 Nov 1;82(1):143-153.

  20. 20.Naidu S, Wijayanti N, Santoso S, Kietzmann T, Immenschuh S. An atypical NF-κ B-regulated pathway mediates phorbol ester-dependent Heme oxygenase-1 gene activation in monocytes. Cell Commun Signal. 2009;7(Suppl 1):A6.

  21. 21.Ortiz-Lazareno PC, Hernandez-Flores G, Dominguez-Rodriguez JR, Lerma-Diaz JM, Jave-Suarez LF, Aguilar-Lemarroy A, Gomez-Contreras PC, Scott-Algara D, Bravo-Cuellar A. MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor-kappaB and activator protein-1.Immunology. 2008 Aug;124(4):534-41.

  22. 22.Lerma-Díaz JM, Hernández-Flores G, Domínguez-Rodríguez JR, Ortíz-Lazareno PC, Gómez-Contreras P, Cervantes-Munguía R, Scott-Algara D, Aguilar-Lemarroy A, Jave-Suárez LF,Bravo-Cuellar A. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation. Immunol Lett. 2006 Mar 15;103(2):149-58.

  23. 23.Mogensen TH. Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses. Clin Microbiol Rev. 2009 Abr 1;22(2):240-273.

  24. 24.Ba X, Gupta S, Davidson M, Garg NJ. Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes. J Biol Chem 2010 Abr 9;285(15):11596-11606.

  25. 25.Ciaramella A, Cavone A, Santucci MB, Garg SK, Sanarico N, Bocchino M, et al. Induction of Apoptosis and Release of Interleukin-1β by Cell Wall-Associated 19-kDa Lipoprotein during the Course of Mycobacterial Infection. J Infect Dis. 2004;190(6):1167-1176.

  26. 26.Tuosto L. NF-κB family of transcription factors: biochemical players of CD28 co-stimulation. Immunol Lett. 2011 Mar 30;135(1-2):1-9.

  27. 27.Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, et al. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF κ B activity and IL-2 production. Pharmacol Res. 2010 May;61(5):405-409.

  28. 28.Huang S, Tsai H, Tzeng H, Liao H, Hsu P. Lipid Raft Assembly and Lck Recruitment in TRAIL Costimulation Mediates NF-κB Activation and T Cell Proliferation. J Immunol. 2011 Ene 15;186(2):931 -939.

  29. 29.Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF κ B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999 Abr;19(4):2690-2698.

  30. 30.Hanief Sofi M. Wei Li, Kaplan Mark H. Chang Cheong-Hee. Elevated IL-6 expression in CD4 T cells via PKCθ and NF-KB induces Th2 cytokine production. Mol Immunol. 2009. 46(7). 1443-1450.

  31. 31.Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-κ B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001 Ene;2(1):45-50.

  32. 32.Moscat J, Diaz-Meco MT, Rennert P. NF-κB activation by protein kinase C isoforms and B-cell function. EMBO Rep. 2003 1;4(1):31-36.

  33. 33.Hayden MS, West AP, Ghosh S. NF-kappaB and the immune response. Oncogene. 2006 Oct 30;25(51):6758-6780.

  34. 34.Linde A, Mosier D, Blecha F, Melgarejo T. Innate immunity and inflammation--New frontiers in comparative cardiovascular pathology. Cardiovasc Res. 2007 Ene 1;73(1):26-36.

  35. 35.Lai Y, Gallo RL. Toll-like receptors in skin infectious and inflammatory diseases. Infect Disord Drug Targets. 2008 Sep;8(3):144-155.

  36. 36.Smallie T, Ricchetti G, Horwood NJ, Feldmann M, Clark AR, Williams LM. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med 2010 Sep 27;207(10):2081-2088.

  37. 37.Israël A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a000158.

  38. 38.Lee CH, Jeon Y, Kim S, Song Y. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007;29(1):19-35.

  39. 39.Magne N, Toillon R, Bottero V, Didelot C, Houtte P, Gerard J, et al. NF-κ B modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Letters. 2006 1;231(2):158-168.

  40. 40.Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J of Leuk Biol. 2009 Nov 1;86(5):1065 -1073.

  41. 41.Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-κ B activation. Cancer Sci. 2008 May;99(5):836-842.

  42. 42.Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese WD, Filleur S. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine. 2011. Available online 13 May 2011.

  43. 43.Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006 Nov 30;72(11):1605-1621.

  44. 44.Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009 Ene 15;15(2):425-430.

  45. 45.Le Page C, Koumakpayi IH, Lessard L, Mes-Masson A, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate. 2005 10;65(2):130-140.

  46. 46.Zheng C, Yin Q, Wu H. Structural studies of NF-κB signaling. Cell Res. 2011 Ene;21(1):183-195.

  47. 47.Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006 May 25;441(7092):431-436.

  48. 48.Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2030;22(56):8999-9006.

  49. 49.Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of κ B kinase pathways in oncogenic initiation and progression. Oncogene. 2006 Oct 30;25(51):6817-6830.

  50. 50.Li Z, Tang Q, Wang J, Zhou L, Huang W, Liu R, et al. Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappaB pathway. J Gastroenterol Hepatol 2010 Jul;25(7):1315-1320.




2020     |     www.medigraphic.com